{
  "docId": "019dd923-622c-750b-8b9a-8c03a48e7d6f",
  "docSlug": "86e21d9d1e23",
  "documentTitle": "PMV Pharmaceuticals (PMVP)",
  "authorId": "60_Wolfpack_Research",
  "authorName": "Wolfpack Research",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2022-05-19 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 7,
  "pageCount": 19,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "villain_critique",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Uses dose conversion to humans as a comparative framework to highlight potential lack of potency/viability.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "line_chart",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-8c03a48e7d6f/7",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-8c03a48e7d6f",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-8c03a48e7d6f.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-8c03a48e7d6f#slide-7",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Doses less than 100 mg/kg do not look effective in generating tumor response.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-70f9-71ae-a678-64098033aa06",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.7,
        "x": 0.15,
        "y": 0.41
      },
      "kind": "chart",
      "text": "PC14586 Single-Agent Administration in NUGC3 Xenograft Model Resulted in Tumor Regression and was Well Tolerated",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f438fd4e-cd91-4e71-9dcd-55ee6c4f1b6e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "tumor volume: 100",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-70f9-71ae-a678-69710a67dfd3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.8,
        "x": 0.1,
        "y": 0.69
      },
      "kind": "paragraph",
      "text": "Doses less than 100 mg/kg do not look effective in generating tumor response. Using a validated practice guideline for dose conversion to humans, this converts to an effective dose of around 570 mg for a 70 kg human.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19c7aa39-8b22-4140-b521-020b470f66bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.8,
        "x": 0.1,
        "y": 0.14
      },
      "kind": "paragraph",
      "text": "PMV claims that PC14586 exhibited single-agent anti-tumor activity in a dose-dependent manner against mutant p53 Y220C tumors. They offered as evidence both potent TGI (see the 25 and 50 mg/kg doses) and tumor regression (see the 100 mg/kg dose).",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ace01f64-1845-4676-a436-75eea1359039",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.15,
        "x": 0.15,
        "y": 0.64
      },
      "kind": "source-note",
      "text": "Source: Form S/1 (September 2020)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bdcea4fe-f085-4302-bb0b-f281fe1d22f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.1,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "11 Represented in 10-K, 13, 3/1/2022",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f86cb865-61e9-41ae-8017-c7ec18131a15",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.1,
        "y": 0.09
      },
      "kind": "title",
      "text": "PMV’s Preclinical Experiments on Mice Suggest a Competing Product Appears 100 Times More Potent than PC14586",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60f0a429-0f69-4c54-b08d-8d7c801e2b53",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "dose-conversion-to-humans",
      "slug": null,
      "matchId": "8f7af3b7-e0ed-46d1-995c-35131094a5a9",
      "evidence": "Used to compare mouse efficacy doses to human equivalent doses for oncology drugs.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 12,
      "from": 3,
      "beatId": "f89a3578-3b10-48a0-a0dc-890f21967937",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Monster",
      "beatSlug": "overcoming-monster-the-monster",
      "evidence": "The document exposes contradictions and concerns regarding PMV Pharma's drug candidate.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Hook",
      "parentBeatSlug": "hook"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 4,
      "name": "Aha Moment",
      "slug": "03-aha-moment",
      "bestFor": "Data-heavy sections, research findings, analytical arguments",
      "matchId": "d5c00e43-039c-461c-a756-55cffee7cf74",
      "evidence": "The document highlights several concerns regarding PMV Pharma's preclinical study results.",
      "position": 0,
      "objective": "Raises concerns about the drug's selectivity and efficacy",
      "structure": "The Problem/Question -> What the Data Shows -> The Insight",
      "confidence": 0.7,
      "description": "Establish a tension, present data, then deliver the insight that changes everything"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}